Analysts: Johnson & Johnson’s Zytiga Boosts Market Share and 3 Other Research Notes to Read
Johnson & Johnson (NYSE:JNJ): After analyzing third-party data, Wells Fargo estimates that the market share of Johnson & Johnson’s Zytiga drug rose to 47 percent in July from 42 percent in June. The firm continues to expect Zytiga usage to remain strong throughout the second half of 2013, and it keeps an Outperform rating on the stock.
Pacific Sunwear (NASDAQ:PSUN): After Pacific Sunwear reported stronger-than-expected second-quarter results but provided weaker-than-expected third-quarter guidance, Wedbush views the guidance as conservative. It recommends investors respond to any weakness related to the guidance by buying the stock.
GameStop (NYSE:GME): Bank of America/Merrill Lynch was impressed with the content displayed at GameStop’s 2013 Expo and said enthusiasm for next-generation consoles is very high. The analyst believes GameStop has a critical advantage over peers due to store employee knowledge and that its PowerUp and trade-in program will allow it to dominate the new console cycle. The shares are rated a Buy with a $62 price target.
Micron (NASDAQ:MU): Roth Capital has raised its Micron estimates following the closure of the Elpida deal. The firm expects improving margins due to a focus on higher margin server, networking, smartphone/tablet DRAM, and NAND flash. The firm keeps a Buy rating on the shares while raising its price target from $15 to $21.